Results 141 to 150 of about 13,218 (206)

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study. [PDF]

Pharmaceuticals (Basel)
De Bellis E, Donnarumma D, Pagano A, Mazza I, Charlier B, Madonia S, Masullo A, Onofrio M, Fortunato V, Spera AM, Campana F, Franci G, Salzano F, Corbi G, Filippelli A, Pagliano P, Conti V.   +16 more
europepmc   +1 more source

Never Too Late: A Case Report of Severe Fanconi Syndrome Developing After More than a Decade of Silent Tenofovir Disoproxil Fumarate Exposure. [PDF]

Reports (MDPI)
Petrakis V, Themelidis D, Panopoulou M, Kriki P, Valsamaki PN, Papazoglou D, Panagopoulos P.   +6 more
europepmc   +1 more source

Evolution and forecasting of antiretroviral therapy utilisation in British Columbia: a population-level analysis of provincial drug treatment programme data, 2014-2024. [PDF]

BMJ Open
Lima VD, Mokhtari Jazi A, Montaner JSG.
europepmc   +1 more source

The fate of ritonavir in the presence of darunavir

International Journal of Pharmaceutics, 2014
This study was the first investigation into the potential of a fixed dose combination of ritonavir and darunavir in the form of dispersible powders prepared by spray drying.
G van den Mooter
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Darunavir

Drugs of Today, 2007
Darunavir is a nonpeptidic protease inhibitor recently approved for the treatment of antiretroviral therapy-experienced patients. It has potent in vitro activity against viral isolates that are resistant to currently licensed protease inhibitors. In randomized clinical trials with optimized background regimens, it has shown virologic and immunologic ...
Wissam I, El-Atrouni, Zelalem, Temesgen
openaire   +4 more sources

Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients

Pharmacological Research, 2012
The potential drug-to-drug interaction between darunavir and raltegravir in the setting of HIV infection is a highly debated issue still unresolved.
Emilio Clementi, Cristina Gervasoni, Giuliano Rizzardini   +2 more
exaly   +2 more sources